Observational studyScientific reports2024
Radiomics analysis for distinctive identification of COVID-19 pulmonary nodules from other benign and malignant counterparts.
Observational study in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
- Radiomics-derived classifier performance evaluation in lung nodule characterization compared with expert radiologists.Scientific reports · 2026Article
- Integrating Surgery and Ablative Therapies for the Management of Multiple Primary Lung Cancer: A Systematic Review.Cancers · 2025Review
- Staging CT chest for cT1a renal masses: Does it change management?BJUI compass · 2025Article
- Radiomics: Assessing Significance and Correlation with Ground-Truth Data in Precision Medicine in Lung Adenocarcinoma.Bioengineering (Basel, Switzerland) · 2025Article
- Radiomics for differentiating adenocarcinoma and squamous cell carcinoma in non-small cell lung cancer beyond nodule morphology in chest CT.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This observational study investigated the potential of radiomics as a non-invasive adjunct to CT in distinguishing COVID-19 lung nodules from other benign and malignant lung nodules. Lesion segmentation, feature extraction, and machine learning algorithms, including decision tree, support vector machine, random forest, feed-forward neural network, and discriminant analysis, were employed in the radiomics workflow. Key features such as Idmn, skewness, and long-run low grey level emphasis were identified as crucial in differentiation. The model demonstrated an accuracy of 83% in distinguishing COVID-19 from other benign nodules and 88% from malignant nodules. This study concludes that radiomics, through machine learning, serves as a valuable tool for non-invasive discrimination between COVID-19 and other benign and malignant lung nodules. The findings suggest the potential complementary role of radiomics in patients with COVID-19 pneumonia exhibiting lung nodules and suspicion of concurrent lung pathologies. The clinical relevance lies in the utilization of radiomics analysis for feature extraction and classification, contributing to the enhanced differentiation of lung nodules, particularly in the context of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.